Do you handle HTA dossiers and pricing negotiations directly?
Answers from the sources
regenold GmbH
“Health economics, value dossier authoring, and payer negotiations are specialist disciplines that require dedicated expertise. We bring in specialist market access partners for this work, the same way we bring in CROs for clinical operations or CDMOs for manufacturing.”
Sourceregenold.com
Continue exploring
About these subjects
Related reading
- How do I handle informed consent under both the CTR and GDPR?
- What should we be ready to show in an inspection?
- How does the EU HTA Regulation affect my market access strategy?
- What happens when my EDC or safety database provider has servers outside the EU?
- Do I need a DPO for my clinical trial?
- How has ICH E6(R3) changed how you design trials?
- Do we need documentation if AI is "just drafting"?
- How quickly can you mobilise a DD team?
- Do you work on both buy-side and sell-side mandates?
- What does it mean when you “act as sponsor” for an EU clinical trial?
- What is the difference between an EU sponsor and an EU legal representative?
- How do we qualify a vendor AI tool?
- Do you support ISO 27001 certification, and are you certified yourselves?
- What is the difference between a site visit during DD and a formal GMP audit?
- How do you coordinate between the regulatory submission and market entry?
- What market entry infrastructure can you provide directly?
- What happens if data is incomplete or access is restricted during the process?
- regenold GmbH — company guide
Data formats and record details
Download this recordapplication/json
- Surface ID
- urn:readyscan:corpus:buyer-question:regenold-gmbh-q140571087-answer-ad0e76bb92db40823d71
- Material fingerprint
- fnv1a64:029183d6eae94384
- Membership fingerprint
- fnv1a64:ebfa9a6744ac32d8
- Published
- 2026-10-26
- Modified
- 2026-10-26
- ready-scan-subjects/Q140571087
- revision Q140571087:content:42d5154a2e8358d1